Ercanetide

Ercanetide
Clinical data
Other namesCyclo(L-glycyl-L-2-allylproline)
Legal status
Legal status
  • Investigational
Identifiers
  • (8aR)-8a-Prop-2-enyl-3,6,7,8-tetrahydro-2H-pyrrolo[1,2-a]pyrazine-1,4-dione
CAS Number
PubChem CID
DrugBank
ChemSpider
UNII
ChEMBL
Chemical and physical data
FormulaC10H14N2O2
Molar mass194.234 g·mol−1
3D model (JSmol)
  • C=CC[C@@]12CCCN1C(=O)CNC2=O
  • InChI=1S/C10H14N2O2/c1-2-4-10-5-3-6-12(10)8(13)7-11-9(10)14/h2H,1,3-7H2,(H,11,14)/t10-/m0/s1
  • Key:WVKCGUOWPZAROG-JTQLQIEISA-N

Ercanetide (INNTooltip International Nonproprietary Name;[1] developmental code name NNZ-2591) is a synthetic analog of cyclic glycine-proline (cGP) and experimental drug developed for Angelman syndrome, Phelan-McDermid syndrome, Pitt Hopkins syndrome,[2][3] and Prader-Willi syndrome.[4]

See also

References

  1. ^ https://cdn.who.int/media/docs/default-source/international-nonproprietary-names-(inn)/pl133.pdf
  2. ^ Markati, Theodora; Duis, Jessica; Servais, Laurent (3 July 2021). "Therapies in preclinical and clinical development for Angelman syndrome". Expert Opinion on Investigational Drugs. 30 (7): 709–720. doi:10.1080/13543784.2021.1939674. PMID 34112038.
  3. ^ Heussler, Helen S. (March 2021). "Emerging Therapies and challenges for individuals with Angelman syndrome". Current Opinion in Psychiatry. 34 (2): 123–128. doi:10.1097/YCO.0000000000000674. ISSN 0951-7367. PMID 33395098. S2CID 230663523.
  4. ^ "An Open-Label Study of Oral NNZ-2591 in Prader-Willi Syndrome (PWS-001) (PWS-001) NCT05879614". clinicaltrials.gov. Retrieved 6 December 2023.
This article is issued from Wikipedia. The text is available under Creative Commons Attribution-Share Alike 4.0 unless otherwise noted. Additional terms may apply for the media files.